Introduction {#sec1}
============

Asthma, a heterogeneous disease, is the most common long-term inflammatory disease of the lung airways, remaining a major cause of disability, health resource utilization and poor quality of life worldwide \[[@B1],[@B2]\]. It is characterized by the presence of recurring respiratory symptoms, reversible airflow obstruction and bronchospasm \[[@B3]\]. Its symptoms include episodes of wheezing, chest tightness, shortness of breath and coughing, occurring a few times a day or a week depending on the single individual \[[@B4]\]. According to the World Health Organization, it is estimated that 235 to 330 million people currently suffer from asthma, and approximately 250000 to 345000 people die from this disease per year throughout the world \[[@B5]\]. The risk factors such as tobacco smoking, indoor allergens, obesity, diet, air pollution and social factors might contribute to the development of asthma \[[@B6],[@B7]\]**.** In addition, an elevation of serum IgE level is considered as a potent predictor of asthma course \[[@B8]\]. Although great advances for the development of asthma controller therapies have been made and death rates due to asthma have reduced greatly over these years, no available therapeutic regimens can cure this disease and its burden will continue to be driven by increasing prevalence \[[@B9]\]. Therefore, there is an urgent need to identify some biomarkers to predict this disease and create a guideline for the therapeutic strategies.

Recent progresses in molecular biology suggest complex interactions of innate and adaptive immune cells, structural cells and their cytokines involved in the process of airway inflammation \[[@B10],[@B11]\]. A growing number of evidence have shown that interleukins (ILs) are critical to mounting inflammation and immune responses \[[@B12]\]. ILs are a multifunctional group of immunomodulators that primarily mediate the leucocyte cross-talk, and mainly regulate the immune cell proliferation, growth, differentiation, survival, activation and functions \[[@B13]--[@B15]\]. The interleukin-13 (*IL-13*) gene, located on human chromosome 5q31--33, is produced by innate lymphoid cells and T-helper type 2 (Th2) cells during allergic inflammation, containing four exons and three introns and encoding an unglycosylated protein composed of 132 amino acids. The most prominent effects of IL-13 include promotion of differentiation and survival of eosinophils and mast cells, activation of fibroblasts, elevation of bronchial hyperresponsiveness and switching of B-cell antibody production from IgM to IgE \[[@B16]\]. Furthermore, IL-13 inhibition may be beneficial in patients who are refractory to existing therapies \[[@B17]\]. Studies have shown that IL-13 might play a role in human diseases such as allergic airway disease \[[@B18]\], fibrosis \[[@B19]\] and renal cell carcinoma \[[@B20]\]. Genetic polymorphisms in *IL-13* gene might influence its function, thus involved in the pathogenicity of asthma. One of the most studied single nucleotide polymorphisms (SNPs) was +1923C/T (rs1295686) in third intron at the intron/exon boundary. This variant was shown to be involved in the dysregulation of total IgE \[[@B21]\].

Several studies have identified the role of IL-13 +1923C/T polymorphism in asthma susceptibility; however, the results obtained from different geographical populations were very different. For example, Ramphul et al. \[[@B22]\] found that IL-13 +1923C/T locus had a significant effect predisposed to asthma in Mauritian Indian children, not in Chinese Han population. Moreover, the prevalence rates of asthma vary between countries, ranging from 1 to 18% and it is more common in developed than in developing countries \[[@B23]\]. Also, genetic associations with asthma can differ significantly among different ethnic populations \[[@B24],[@B25]\]. Therefore, we conducted this meta-analysis to reassess the association of IL-13 +1923C/T polymorphism with asthma risk based on all the available case-control studies.

Materials and methods {#sec2}
=====================

Study identification {#sec2-1}
--------------------

The electronic databases of Medline, Embase, PubMed, Chinese National Knowledge Infrastructure (CNKI) and Wanfang were comprehensively searched to retrieve relevant articles published between January 2000 and July 2016. The following medical subject heading (MeSH) terms: "asthma or asthmatic", "cytokines or interleukin or interleukin-13 or IL-13" and "polymorphism or variant or SNP" as well as their combinations were employed as the searching keywords. The corresponding Chinese version was used in the Chinese databases. To obtain more data, we manually searched the references of related articles. Our analysis only focused on the studies that were written in English and Chinese. When the same authors or laboratories reported this issue on the same population, only the latest published full-text article was included.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

The included studies must meet the following criteria: (i) case-control studies evaluating the correlation of IL-13 +1923C/T polymorphism in asthma risk; (ii) patients with asthma were defined according to the Guidelines of the American Thoracic Society \[[@B26]\] or other diagnostic criteria \[[@B27]\]; controls should be unrelated ethnically matched individuals with no symptoms or history of allergy and other pulmonary diseases; (iii) genotype information in patients and controls was available to extract; and (iv) the genotype distribution in controls should be in consistence with Hardy--Weinberg equilibrium (HWE). The exclusion criteria were: (i) without the control group; (ii) conference papers or review reports; (iii) data cannot be extracted; and (iv) with duplicated data.

Data extraction {#sec2-3}
---------------

Two of our authors independently assessed the extracted information of each included study. Any disagreement was resolved by discussion with a third author. Each item should be able to reach a final consensus. The following information was extracted from each article: the name of first author, published year, country, ethnicity, mean age, sample size, genotyping methods, genotype distribution and HWE in controls.

Statistical analysis {#sec2-4}
--------------------

The association between IL-13 +1923C/T polymorphism and asthma risk was measured by pooled odds ratio (OR) with 95% corresponding confidence intervals (CIs). The significance of the pooled OR was determined by the *Z*-test and a *P* value less than 0.05 was considered significant. The allelic model (T compared with C), homozygote model (TT compared with CC), heterozygote model (CT compared with CC), dominant model (TT + CT compared with CC) and recessive model (TT compared with CT + CC) were calculated. The *I*^2^-test and the Q-statistic test were employed to determine the between-study heterogeneity. The fixed-effect model was used when the *P*-value for the Q-test was more than 0.10 and *I*^2^ for the *I*^2^ test was \<50%; otherwise, the random-effect model was used. Funnel plot was used to assess the publication bias. Analyses were performed using the software Review Manage 5.3 (Oxford, England, U.K.).

Results {#sec3}
=======

Main characteristics of selected studies {#sec3-1}
----------------------------------------

[Figure 1](#F1){ref-type="fig"} outlined the study process of selection. Briefly, we first identified 798 articles. After applying the inclusion and exclusion criteria, a total of 26 articles including 17642 asthma patients and 42402 controls were screened out. Of the 26 articles, 12 were written in Chinese \[[@B28]--[@B39]\] and 14 in English \[[@B40]--[@B53]\]. Among them, 17 were conducted in Asian populations, five in Caucasian populations and four in African populations. One article contained two study populations. The IL-13 +1923C/T polymorphism was measured by 11 different methods. The genotypes of IL-13 +1923C/T polymorphism in controls were all in accordance with HWE (*P*\>0.05). [Table 1](#T1){ref-type="table"} listed the main characteristics of included studies. [Table 2](#T2){ref-type="table"} exhibited the distribution information of alleles and genotypes of IL-13 +1923C/T polymorphism. Figure 1Flow chart of selection process in this meta-analysis Table 1Main characteristics of included studies in this meta-analysisFirst authorYearCountryEthnicityMean ageSample sizeGenotyping methodsCasesControlsCasesControlsHákonarson, H.2001IcelandCaucasian38 (12--59)38 (12--59)9494PCRChen, J.Q.2004ChinaAsian2.59 ± 1.442.90 ± 1.459653PCR-RFLPDonfack, I, J.2005U.S.A.CaucasianNANA126205LASDonfack, II, J.2005U.S.A.AfricanNANA205183LASSong, Z.Q.2005ChinaAsian14--6718--70100100PCR-RFLPBattle, N.C.2007U.S.A.African19.4 (7.3--40.9)29.8 (8.2--41.2)264176PCR-RFLPShi, X.H.2008ChinaAsian34 (14--66)18--564848PCR-RFLPDaley, D.2009AustraliaCaucasianNANA644751Illumina Bead Array SystemWang, X.H.2009ChinaAsian39 ± 1148 ± 12150160PCR-RFLPLi, X.N.2010U.S.A.Caucasian46.9 ± 18.431.4 ± 21.94731892Illumina HumanCNV370 BeadChipMoffatt, M.F.2010MixedCaucasianNANA1036516110Illumina Human610 quad arrayWu, X.H.2010ChinaAsian8.8 ± 3.29.2 ± 2.8252227PCR-RFLPNoguchi, E.2011JapanAsian8.0 ± 4.460.3 ± 14.29382376TaqManEl-Behady, E.M.2012EgyptAfrican9.3 ± 1.89.2 ± 1.65030PCR-RFLPYoon, D.K.2012KoreaAsian52.2 ± 8.952.2 ± 8.923716095Afymetrix Genome-Wide Human SNP array 5.0Jia, C.M.2013ChinaAsian4.27 ± 2.524.15 ± 2.917750PCR-RFLPKelibiena, T.2013ChinaAsian38.35 ± 9.1738.12 ± 8.237689PCR-RFLPLiu, Q.H.2013ChinaAsian3--12NA384384TaqManPu, H.P.2013ChinaAsian5.8 ± 2.95.6 ± 2.69696PCR-RFLPWang, Y.2014ChinaAsian3--123--12435601SNaPshot assayXia, M.Q.2014ChinaAsian6.30 ± 3.394.96 ± 3.61305200PCR-RFLPXu, J.X.2014ChinaAsian7.5 ± 8.28.4 ± 8.8230220SequenomRamphul, K.2015MauritiusAfrican3--1218--22193189TaqManXi, S.Y.2015ChinaAsian20--6518--66100100PCR-RFLPLi, T.X.2016ChinaAsian5.06 (4.0--8.0)5.00 (4.0--8.0)652752SnaPshot assayTang, M.F.2016ChinaAsian2--72--79031205TaqManWang, H.L.2016ChinaAsian8 ± 1.76.6 ± 2.017356PCR-RFLP[^1]

###### 

Distribution information of alleles and genotypes in IL-13 +1923C/T polymorphism among asthma patients and controls

  First author      Cases   Controls                                                             
  ----------------- ------- ---------- ----- ------- ------ ------- ------ ------ ------- ------ -------
  Hákonarson, H.    65      27         2     157     31     64      27     3      155     33     0.997
  Chen, J.Q.        41      43         12    125     67     39      14     0      92      14     0.541
  Donfack, I, J.    72      45         9     189     63     120     77     8      317     93     0.598
  Donfack, II, J.   18      101        86    137     273    25      75     83     125     241    0.486
  Song, Z.Q.        24      55         21    103     97     43      47     10     133     67     0.860
  Battle, N.C.      31      117        113   179     343    21      77     72     119     221    0.998
  Shi, X.H.         12      26         10    50      46     30      16     2      76      20     0.997
  Daley, D.         422     199        23    1043    245    516     213    22     1245    257    0.939
  Wang, X.H.        31      57         61    119     179    66      68     26     200     120    0.498
  Li, X.N.          278     167        28    723     223    1247    578    67     3072    712    0.998
  Moffatt, M.F.     6306    3558       501   16170   4560   10310   5156   644    25776   6444   0.984
  Wu, X.H.          106     114        32    326     178    126     85     16     337     117    0.949
  Noguchi, E.       387     439        112   1213    663    1125    1025   226    3275    1477   0.944
  El-Behady, E.M.   20      20         10    60      40     25      5      0      55      5      0.883
  Yoon, D.K.        110     99         28    319     155    7729    6768   1580   22226   9928   0.081
  Jia, C.M.         22      42         13    86      68     25      22     3      72      28     0.812
  Kelibiena, T.     37      26         13    100     52     66      19     4      151     27     0.274
  Liu, Q.H.         174     164        46    512     256    179     169    36     527     241    0.912
  Pu, H.P.          39      45         12    123     69     67      24     5      158     34     0.379
  Wang, Y.          182     191        62    555     315    291     246    64     828     374    0.542
  Xia, M.Q.         84      128        93    296     314    95      73     32     263     137    0.997
  Xu, J.X.          150     71         9     371     89     151     62     7      364     76     0.979
  Ramphul, K.       78      79         25    235     129    77      96     13     250     122    0.066
  Xi, S.Y.          21      41         38    83      117    41      44     15     126     74     0.854
  Li, T.X.          304     290        58    898     406    355     316    81     1026    478    0.698
  Tang, M.F.        345     439        110   1129    659    512     530    150    1554    830    0.781
  Wang, H.L.        38      58         77    134     212    24      23     9      71      41     0.690

Association of IL-13 +1923C/T polymorphism in asthma risk {#sec3-2}
---------------------------------------------------------

[Table 3](#T3){ref-type="table"} presented the genetic effect of IL-13 +1923C/T variant on asthma risk. The between-study heterogeneity was detected (*P\<*0.01 and *I*^2^\>50%), and the random-effect model was employed. Overall, the frequency of T allele of IL-13 +1923C/T polymorphism was found to be a little higher in asthma patients than that in controls (27.9% compared with 26.2%), and the statistical analysis demonstrated that this allele was significantly related with increased asthma susceptibility (T compared with C: OR=1.44, 95% CI= 1.30--1.60, *P*\<0.00001) as shown in [Figure 2](#F2){ref-type="fig"}. This significant association was obtained in other genetic models as well (TT compared with CC: OR=1.93, 95% CI=1.57--2.37, *P*\<0.00001; CT compared with CC: OR=0.32, 95% CI=1.20--1.46, *P*\<0.00001; TT + CT compared with CC: OR=1.49, 95% CI=1.32--1.68, *P*\<0.00001; TT compared with CT + CC: OR=1.59, 95% CI=1.34--1.89, *P*\<0.00001). Figure 2Meta-analysis of the correlation between the IL-13 +1923C/T polymorphism and asthma risk under the allelic model Table 3Summary of the genetic effect of IL-13 +1923C/T variant on asthma risk and subgroup analysesGroupsComparisons*N*Test of associationTest of heterogeneityOR (95% CI)*PI*^2^PhModelTotalT compared with C261.44 (1.30, 1.60)\<0.0000183%\<0.00001RTT compared with CC1.93 (1.57, 2.37)\<0.0000173%\<0.00001RCT compared with CC1.32 (1.20, 1.46)\<0.0000159%\<0.0001RTT + CT compared with CC1.49 (1.32, 1.68)\<0.0000176%\<0.0001RTT compared with CT + CC1.59 (1.34, 1.89)\<0.0000167%\<0.0001RAsianT compared with C171.66 (1.41, 1.95)\<0.0000186%\<0.00001RTT compared with CC2.34 (1.72, 3.18)\<0.0000179%\<0.00001RCT compared with CC1.46 (1.27, 1.69)\<0.0000160%0.0005RTT + CT compared with CC1.74 (1.45, 2.08)\<0.0000178%\<0.00001RTT compared with CT + CC1.85 (1.43, 2.39)\<0.0000173%\<0.00001RCaucasianT compared with C51.14 (1.09, 1.18)\<0.000010%0.41FTT compared with CC1.30 (1.16, 1.46)\<0.000010%0.46FCT compared with CC1.31 (1.08, 1.19)\<0.000010%0.72FTT+CT compared with CC1.15 (1.10, 1.21)\<0.000010%0.56FTT compared with CT + CC1.25 (1.11, 1.40)0.00010%0.52FAfricanT compared with C41.32 (0.88, 1.98)0.1879%0.003RTT compared with CC1.59 (1.09, 2.31)0.0245%0.14FCT compared with CC1.45 (0.77, 2.74)0.2573%0.01RTT + CT compared with CC1.60 (0.83, 3.08)0.1677%0.005RTT compared with CT + CC1.26 (0.76, 2.09)0.3863%0.04RAdultT compared with C61.66 (1.20, 2.31)0.00286%\<0.00001RTT compared with CC2.61 (1.42, 4.79)0.00278%0.0004RCT compared with CC1.27 (1.10, 1.48)0.00142%0.12FTT + CT compared with CC1.66 (1.18, 2.34)0.00477%0.0007RTT compared with CT + CC2.19 (1.35, 3.56)0.00270%0.006RChildrenT compared with C141.50 (1.27, 1.77)\<0.0000184%\<0.00001RTT compared with CC1.90 (1.40, 2.57)\<0.000173%\<0.00001RCT compared with CC1.38 (1.17, 1.62)\<0.000164%0.0006RTT + CT compared with CC1.56 (1.29, 1.89)\<0.0000178%\<0.00001RTT compared with CT + CC1.59 (1.23, 2.07)0.000467%0.0002R[^2]

Subgroup analysis by ethnicity and age group of the association between IL-13 +1923C/T polymorphism and asthma risk {#sec3-3}
-------------------------------------------------------------------------------------------------------------------

In the stratified analysis by ethnicity, 17 articles including 5242 asthma patients and 22781 controls were conducted in Asians, five articles including 11702 patients and 19052 controls in Caucasians, and four articles including 698 patients and 569 controls in Africans. Overall, we found that IL-13 +1923C/T variant was associated with increased asthma susceptibility among Asians under each genetic model (T compared with C: OR=1.66, 95% CI=1.41--1.95, *P*\<0.00001; TT compared with CC: OR=2.34, 95% CI=1.72--3.18, *P*\<0.00001; CT compared with CC: OR=1.46, 95% CI=1.27--1.69, *P*\<0.00001; TT + CT compared with CC: OR=1.74, 95% CI=1.45--2.08, *P*\<0.00001; TT compared with CT + CC: OR=1.85, 95% CI=1.43--2.39, *P*\<0.00001). This statistical significance was detected in Caucasians as well (T compared with C: OR=1.14, 95% CI=1.09--1.18, *P*\<0.00001; TT compared with CC: OR=1.30, 95% CI=1.16--1.46, *P*\<0.00001; CT compared with CC: OR=1.31, 95% CI=1.08--1.19, *P*\<0.00001; TT + CT compared with CC: OR=1.15, 95% CI=1.10--1.21, *P*\<0.00001; TT compared with CT + CC: OR=1.25, 95% CI=1.11--1.40, *P*=0.0001). However, only TT genotype under the homozygote model was related with increased risk of asthma in Africans (TT compared with CC: OR=1.59, 95% CI=1.09--2.31, *P*=0.02) in the fixed-effect model. [Figure 3](#F3){ref-type="fig"} showed the relationship between TT genotype of +1923C/T variant and asthma risk under the homozygote model among Asians, Caucasians and Africans respectively.

![Forest plot of the relative strength of the association between IL-13 +1923C/T polymorphism and asthma risk under the homozygote model among Asians, Caucasians and Africans](BSR-2016-0505fig003){#F3}

In the stratified analysis by age group, 14 articles containing 4764 cases and 6423 controls were performed in children (\<18 years old), six articles containing 1129 cases and 18412 controls were in adults (≥18 years old) and the other six were mixed age group. Our result identified that IL-13 +1923C/T variant correlated with increased risk of asthma in both children and adult groups under each genetic model ([Table 3](#T3){ref-type="table"}). The significant effect was higher in children group than that in adult group. [Figure 4](#F4){ref-type="fig"} showed the relationship between T allele of IL-13 +1923C/T polymorphism and asthma risk in children and adults respectively.

![Meta-analysis of correlation of IL-13 +1923C/T polymorphism in asthma in children and adults](BSR-2016-0505fig004){#F4}

Association of IL-13 +1923C/T polymorphism in IgE levels (k-units/l) {#sec3-4}
--------------------------------------------------------------------

Eight articles reported the association between IL-13 +1923C/T polymorphism and IgE levels in serum; however, the relevant data could only be extracted from five of them, including 569 asthma patients and 399 controls. The statistical analysis found that the TT, CT and CC genotypes in asthma group were all significantly associated with increased IgE levels in serum when compared with controls as shown in [Figure 5](#F5){ref-type="fig"}.

![Forest plot of the association between TT (A), CT (B) and CC (C) genotypes of IL-13 +1923C/T polymorphism and IgE level (k-units/l) of patients with asthma](BSR-2016-0505fig005){#F5}

Sensitivity analysis and publication bias {#sec3-5}
-----------------------------------------

We omitted each particular study to verify whether our results were influenced by each included study or not. The pooled ORs were not materially altered. The funnel plot was used to evaluate the publication bias. All the plots were found to be roughly symmetrical, indicating no publication bias presented as shown in [Figure 6](#F6){ref-type="fig"}.

![Funnel plot of IL-13 +1923C/T polymorphism in asthma risk under the heterozygote model](BSR-2016-0505fig006){#F6}

Discussion {#sec4}
==========

In this meta-analysis, we retrieved a total of 26 relevant articles. Our results found that IL-13 +1923C/T polymorphism was significantly associated with increased risk of asthma under each genetic model. Subgroup analysis by ethnicity showed that the alleles and genotypes of this genetic variant correlated with asthma susceptibility among Asians and Caucasians, but only TT genotype under the homozygote model in Africans. This variant was related with increased risk of asthma in both children group and adult group under each genetic model as well. Furthermore, the TT, CT and CC genotypes in asthma group were all significantly associated with increased IgE levels in sera of asthma patients when compared with controls. Our result was consistent with previous meta-analysis conducted by Liu et al. \[[@B54]\], which contained ten included studies and suggested that IL-13 +1923C/T polymorphism was a risk factor for asthma.

Asthma is a hereditary disorder that is caused by a combination of intrinsic factors and environmental exposure \[[@B55]\]. Exposure to allergens is one of the environmental factors. In response to allergen presentation by airway DCs, T-helper lymphocytes of the adaptive immune system control many aspects of the disease through secretion of IL-4, IL-5, IL-13, IL-17 and IL-22, and these are counterbalanced by cytokines produced by Treg cells \[[@B56]\]. IL-13 is a key Th2 cytokine that directs many of the important features of airway inflammation and remodelling in patients with allergic asthma \[[@B57]\]. The IL-13 transcriptional "signature" can be used to identify individuals with "Th2 high" and "Th2 low" asthma \[[@B58]\]. IL-13 induces characteristic changes in mRNA \[[@B59]\] and miRNA \[[@B60]\] expression patterns in airway epithelial cells, and it induced protein periostin that is secreted basally from airway epithelial cells and can be used as a biomarker for Th2 high asthma \[[@B61]\]. Furthermore, sputum IL-13 levels could serve as a useful biomarker for asthma control assessment \[[@B62]\]. Current studies have identified that target IL-13 pathway is a promising therapeutic approach for asthma \[[@B63],[@B64]\]. The association of IL-13 with asthma pathology and reduced corticosteroid sensitivity suggests a potential benefit of anti-IL-13 therapy in refractory asthma \[[@B65],[@B66]\].

Asthma is primarily an inflammatory disorder of the airways associated with Th2 cell-dependent promotion of IgE production and recruitment of mast cells \[[@B67]\]. The elevated level of total IgE and allergy-specific IgE may function as independent risk factors for asthma \[[@B68]--[@B70]\]. IL-13 is known to be a key regulator in IgE synthesis. IgE production in allergic asthma patients is more dependent on IL-13 than in non-atopics, due to enhanced IL-13 production and to enhance IgE production in response to IL-13 \[[@B71]\]. SNPs in IL-13 were shown to be associated with allergic phenotypes in several ethnically diverse populations and might affect IgE level \[[@B72]\]. Allelic variation in the IL-13 gene was robustly confirmed as a contributor to the variance of IgE levels \[[@B74]\]. T allele of IL-13 +1923C/T was highly significant associated with total serum IgE (*P*=0.00022) \[[@B51]\]. Li et al. \[[@B75]\] found this variant was significantly associated with asthma risk in Chinese children and adults. The potential mechanism might be that: IL-13 +1923C/T variant is located in the third intron of *IL-13* gene. The +1923C was easy to be DNA methylated, thus inhibiting the transcription of *IL-13* gene; while the +1923T variant might suppress this inhibitive effect, thus promoting high expression of IL-13 and serum IgE level. In addition, other IL-13 polymorphisms might be associated with asthma risk as well. IL-13 rs20541 and rs1800925 were risk factors for asthma and rs1800925 was significantly associated with total serum IgE levels \[[@B77]\]. SNP rs848 in the *IL-13* gene region was significantly associated with a continuous measure of symptom severity in adult subjects with severe asthma \[[@B78]\].

Several limitations were presented in our meta-analysis. Firstly, the between-study heterogeneity in any genetic models was high, which might influence the result. Secondly, most of the included studies were conducted in Asian and Caucasian populations, although other ethnicities should be considered. Thirdly, different genotyping methods were used in the respective studies, which may be associated with different call rates. Lastly, the interaction of gene--gene and gene--environment should be considered.

In conclusion, our results suggested that IL-13 +1923C/T polymorphism was a risk factor for asthma susceptibility, especially in Asians and Caucasians. Future large-scale and well-designed studies with more ethnicities are still required to validate the relationship between this genetic polymorphism and asthma risk.
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CI

:   confidence interval

HWE

:   Hardy--Weinberg equilibrium

IL

:   interleukin

IL-13

:   interleukin-13

OR

:   odds ratio

SNP

:   single nucleotide polymorphism

Th2

:   T-helper type 2

[^1]: LAS, multiplex PCR and an immobilized linear array system; NA, not available; PCR-RFLP, PCR-restriction fragment length polymorphism.

[^2]: F, fixed-effect model; *N*, number of included studies; R, random-effect model.
